Published: 2017-04-19 10:15:00 CEST
Nasdaq Nordic

Nasdaq Stockholm Welcomes Annexin Pharmaceuticals to First North

Stockholm, April 19, 2017 — Nasdaq (Nasdaq: NDAQ) announces that the trading in Annexin Pharmaceuticals AB’s shares (short name: ANNX) commenced today on Nasdaq First North in Stockholm. Annexin Pharmaceuticals belongs to the health care sector and is the 29th company to be admitted to trading on Nasdaq’s Nordic markets* in 2017.

Annexin Pharmaceuticals is a biotechnology company developing treatments for vascular diseases with damage and inflammations. The company’s drug candidate, ANXV, is a human protein that can protect and repair blood vessels and prevent inflammations. While the research discovery related to ANXV was made in 2004, Annexin Pharmaceuticals in its current form was founded in 2014. For more information, please visit www.annexinpharma.com.

“This is a joyful day and an important milestone for us,” said Annette Colin Lövgren, CEO of Annexin Pharmaceuticals. “The listing enables us to continue the development of our drug candidate ANXV.”

“We welcome Annexin Pharmaceuticals to Nasdaq First North,” said Adam Kostyál, SVP and Head of European listings at Nasdaq. “Annexin Pharmaceuticals will make a strong addition to our health care sector, and we look forward to supporting them on their continued journey as a publicly traded company.”

Annexin Pharmaceuticals AB has appointed Redeye AB as the Certified Adviser.

*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm.

About Nasdaq First North

Nasdaq First North is regulated as a multilateral trading facility, operated by the different exchanges within Nasdaq Nordic (Nasdaq First North Denmark is regulated as an alternative marketplace). It does not have the legal status as an EU-regulated market. Companies at Nasdaq First North are subject to the rules of Nasdaq First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market.

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables clients to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 85 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,800 listed companies with a market value of $10.1 trillion and nearly 18,000 corporate clients. To learn more, visit: business.nasdaq.com.

Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland, Nasdaq Riga, Nasdaq Stockholm, Nasdaq Tallinn, Nasdaq Vilnius, Nasdaq Clearing and Nasdaq Broker Services are respectively brand names for the regulated markets of Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd., Nasdaq Iceland hf., Nasdaq Riga, AS, Nasdaq Stockholm AB, Nasdaq Tallinn AS, AB Nasdaq Vilnius, Nasdaq Clearing AB and Nasdaq Broker Services AB. Nasdaq Nordic represents the common offering by Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm. Nasdaq Baltic represents the common offering by Nasdaq Tallinn, Nasdaq Riga and Nasdaq Vilnius.

Cautionary Note Regarding Forward-Looking Statements

The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Nasdaq and its products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These factors include, but are not limited to factors detailed in Nasdaq's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.

Media Relations Contact:
Erik Granström
+46 8 405 78 07
erik.granstrom@nasdaq.com
 

 


20170419_Annexin CEO Annette Colin Lövgren.jpg
20170419_Annexin Pharmaceuticals.jpg